Provided by Tiger Trade Technology Pte. Ltd.

MoonLake Immunotherapeutics

15.37
-0.3900-2.47%
Post-market: 15.34-0.0300-0.20%18:14 EDT
Volume:1.14M
Turnover:17.53M
Market Cap:1.31B
PE:-4.03
High:15.69
Open:15.68
Low:15.23
Close:15.76
52wk High:62.75
52wk Low:5.95
Shares:85.11M
Float Shares:55.47M
Volume Ratio:0.92
T/O Rate:2.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8139
EPS(LYR):-3.5300
ROE:-67.47%
ROA:-32.44%
PB:3.05
PE(LYR):-4.35

Loading ...

Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN) and MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Jun 23

MoonLake Shares Rise on Late-Stage Data for Hidradenitis Suppurativa Treatment

Dow Jones
·
Jun 22

MoonLake announces Week 52 results of Phase 3 VELA-1, VELA-2 trials

TIPRANKS
·
Jun 22

MoonLake says Phase 3 VELA trials show sonelokimab hits 67% HiSCR75 at Week 52 in hidradenitis suppurativa

Reuters
·
Jun 22

MoonLake Announces Week 52 Results of Sonelokimab From Its Phase 3 Vela Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

THOMSON REUTERS
·
Jun 22

MoonLake CFO Matthias Bodenstedt sells $351,804 of common shares

Reuters
·
Jun 19

MoonLake CSO Kristian Reich disposes of 150,000 shares for $2.85 million

Reuters
·
Jun 18

Moonlake Immunotherapeutics shareholders approve amended 2022 equity incentive plan, adding 5 million shares

Reuters
·
Jun 10

Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV), MoonLake Immunotherapeutics (MLTX) and MBX Biosciences, Inc. (MBX)

TIPRANKS
·
Jun 09

Moonlake’s Phase 3 Hidradenitis Trial Hits Completion, Setting Up Key Catalyst for MLTX

TIPRANKS
·
Jun 09

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Hinge Health, Inc. Class A (HNGE) and MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Jun 08

MoonLake Immunotherap Price Target Maintained With a $45.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 08

MoonLake Immunotherapeutics (MLTX) Valuation After FDA Progress On Sonelokimab Draws Fresh Investor Attention

Simply Wall St.
·
Jun 06

MoonLake Immunotherapeutics signs commercial supply pact with Vetter Pharma for prefilled application systems

Reuters
·
Jun 01

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), MoonLake Immunotherapeutics (MLTX) and Dogwood Therapeutics (DWTX)

TIPRANKS
·
May 20

LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
May 16

MoonLake Immunotherap Is Maintained at Buy by Needham

Dow Jones
·
May 12

Needham Sticks to Its Buy Rating for MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
May 12

MoonLake Immunotherapeutics : Needham Raises Target Price to $30 From $25

THOMSON REUTERS
·
May 12

MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained

TIPRANKS
·
May 12